LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sesen Bio, Inc. (“Sesen Bio” or “the Company”) (NASDAQ: SESN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between December 21, 2020 and August 17, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 18, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Sesen Bio’s clinical trial for Vicineum suffered from more than 2,000 violations of trial protocols including 215 “major” violations. Three of the Company’s clinical investigators were found guilty of "serious noncompliance," during the clinical trial including "back-dating data.” The Company’s clinical trials showed that Vicineum leaked into the body leading to side effects including liver failure. Vicineum was not likely to achieve FDA approval based on the clinical data that was submitted by the Company. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Sesen Bio, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.